The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial

Schizophrenia Research
Robin EmsleyHarald Murck

Abstract

Worldwide, conventional antipsychotic medication continues to be used extensively, and tardive dyskinesia (TD) remains a serious complication. The primary objective of the present study was to compare the efficacy of EPA versus placebo in reducing symptoms of TD. This was a 12-week, double-blinded, randomized study of ethyl-EPA 2g/day versus placebo as supplemental medication, in patients with schizophrenia or schizoaffective disorder, with established TD. Eighty-four subjects were randomized, of whom 77 were included in the analysis. Both the EPA and placebo groups displayed significant baseline to endpoint improvements in Extrapyramidal Symptom Rating Scale dyskinesia scores, but there were no significant between-group differences (p=0.4). Response rates (>or=30% improvement in TD symptoms) also did not differ significantly between EPA-treated subjects (45%) and placebo-treated subjects (32%) (p=0.6). However, a post-hoc linear mixed model repeated measures analysis of variance indicated an effect for treatment group and duration of TD. The EPA-treated patients had significantly greater mean reductions in dyskinesia scores initially, although this was not sustained beyond 6 weeks. This trial failed to demonstrate an anti-dysk...Continue Reading

References

May 1, 1979·Archives of General Psychiatry·D V JesteR J Wyatt
Apr 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·J A LiebermanJ Kane
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jul 5, 1996·Schizophrenia Research·K S VaddadiG D Burrows
Apr 4, 2001·The International Journal of Neuropsychopharmacology·Robin A. EmsleyDan J. Stein
Jun 5, 2003·The American Journal of Psychiatry·Mary Ann RichardsonLeslie Citrome
Jul 5, 2003·The Annals of Pharmacotherapy·Leigh Anne NelsonSarah N Hausafus
Dec 10, 2003·CNS Drugs·Robin EmsleySusan J van Rensburg
May 28, 2004·The Journal of Clinical Psychiatry·Robin EmsleyPiet P Oosthuizen
Jun 14, 2005·Schizophrenia Research·Guy Chouinard, Howard C Margolese
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators

❮ Previous
Next ❯

Citations

Apr 27, 2011·Current Psychiatry Reports·Vladimir Lerner, Chanoch Miodownik
Apr 14, 2015·Expert Opinion on Pharmacotherapy·Jan Malte BumbF Markus Leweke
Jul 15, 2015·Expert Opinion on Emerging Drugs·Jonathan Tomas Lockwood, Gary Remington
Nov 28, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Norbert MüllerMarkus J Schwarz
Jul 10, 2010·European Psychiatry : the Journal of the Association of European Psychiatrists·R EmsleyD Fincham
Jul 21, 2009·Journal of Psychiatric Research·Jerome SarrisGerard Byrne
Jun 15, 2011·Journal of Psychosocial Nursing and Mental Health Services·Robert H Howland
Jun 20, 2012·The European Journal of Neuroscience·Patricio O'Donnell
May 28, 2014·Early Intervention in Psychiatry·Monika SchlögelhoferNilufar Mossaheb
Jan 6, 2015·Psychiatry and Clinical Neurosciences·Paul P LernerVladimir Lerner
Jun 21, 2015·Neuroscience and Biobehavioral Reviews·Juan C LezaMiguel Bernardo
Jul 30, 2016·Journal of Clinical Medicine·Paola BozzatelloSilvio Bellino
Sep 24, 2011·Journal of Pharmacy Practice·Jessica L Gören, Ashley T Tewksbury
Jul 21, 2006·The Cochrane Database of Systematic Reviews·C B JoyL A Joy
Jan 18, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gregor E BergerPatrick D McGorry
Mar 14, 2019·The Australian and New Zealand Journal of Psychiatry·Myeongju ChoJun Soo Kwon
Aug 16, 2017·Health Technology Assessment : HTA·Hanna BergmanClive E Adams
Jul 29, 2017·Expert Review of Neurotherapeutics·Haitham SalemAntonio L Teixeira
Oct 28, 2019·International Journal of Molecular Sciences·Paola BozzatelloSilvio Bellino
Jan 27, 2018·The Journal of Nervous and Mental Disease·H J Rogier HoendersJoop T V M de Jong
Feb 1, 2013·Clinical Schizophrenia & Related Psychoses·Jeffrey Charles FetterAlan I Green
Jul 6, 2020·Lipids in Health and Disease·Mei-Chi HsuWen-Chen Ouyang
Aug 26, 2020·International Journal of Molecular Sciences·Paola BozzatelloSilvio Bellino
Mar 20, 2018·The Cochrane Database of Systematic Reviews·Karla Soares-WeiserHanna Bergman
Jun 14, 2003·The Cochrane Database of Systematic Reviews·K V Soares-Weiser, C Joy
May 5, 2000·The Cochrane Database of Systematic Reviews·J J McGrath, K V Soares
Feb 9, 2021·Oxidative Medicine and Cellular Longevity·Evgeny A ErmakovLiudmila P Smirnova
Mar 8, 2021·European Archives of Psychiatry and Clinical Neuroscience·Leda L TalibWagner F Gattaz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here